MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
Primary objective of the study is to establish a 3-way PK similarity bridge between MabionCD20 (candidate biosimilar to rituximab), MabThera® (EU-sourced rituximab) and Rituxan® (US-sourced rituximab) following the administration of these drugs to patients with moderate-to-severe rheumatoid arthritis. Main secondary objective is to confirm therapeutic similarity between MabionCD20 and the reference rituximab.
Epistemonikos ID: b2348825eed6c1a98f38001aed121e987b663c90
First added on: Mar 23, 2022